(RTTNews) – Advicenne SA (ALDVI.PA), a French pharmaceutical company focused on rare kidney diseases, announced Monday that the U.S. Food and Drug Administration has accepted for review the New Drug Application or NDA for Sibnayal for the treatment of distal Renal Tubular Acidosi